Current Edition

Regional News

After launch limitations, Johnson & Johnson exec touts manufacturing progress on CAR-T drug Carvykti

As Johnson & Johnson and Legend Biotech have sought to grow the reach of their multiple myeloma CAR-T drug Carvykti since winning FDA approval last year, they've...
Continue Reading →
Regional News

Biogen lays off staffers at newly acquired Reata, with 113 set to lose positions

Just two weeks after Biogen completed its buyout of Reata Pharmaceuticals, the combined company is trimming its staff. In a recent Worker Adjustment and Retrainin...
Continue Reading →
Regional News

BMS doubles down on its early-stage partnership with cell therapy manufacturer Cellares

Six weeks after cell and gene therapy manufacturer Cellares revealed that Bristol Myers Squibb would use its innovative robotic production program, the com...
Continue Reading →
Regional News

Bayer christens $250M cell therapy ‘launch facility’ in Berkeley

Despite the promise of cell therapies, manufacturing the personalized medicines at scale has been a limiting factor for many companies. Now, as BlueRock Therapeutics...
Continue Reading →
Regional News

Merck’s Keytruda hits overall survival goal in early lung cancer as FDA decision nears

What doctors described as a “messy” treatment landscape in early-stage non-small cell lung cancer (NSCLC) could get clearer thanks to a first-in-class overall surviv...
Continue Reading →
Regional News

Boehringer Ingelheim embraces dual-pricing tactic with launch of unbranded Humira biosimilar

Boehringer Ingelheim, which recently launched the first interchangeable biosimilar to AbbVie’s megablockbuster Humira, is getting in on the industry’s double-pricing...
Continue Reading →
Regional News

In splitting from Novartis, Sandoz makes muted market debut

After more than a year of preparation, Sandoz has officially parted ways with Swiss drug giant Novartis. But the company's day-one valuation lagged what some analyst...
Continue Reading →
Regional News

Colombia, pursuing healthcare savings, plots compulsory license for ViiV’s HIV drug dolutegravir

After sparring with GSK’s ViiV Healthcare over the price of its HIV medication dolutegravir, Colombia appears to be taking matters into its own hands. Colombian a...
Continue Reading →
Regional News

Amgen, AbbVie, Gilead, Merck and more form coalition to push back on FTC’s M&A reforms

The Federal Trade Commission (FTC) recently came up short in its attempt to derail Amgen’s $27.8 billion acquisition of Horizon Therapeutics. But there is still cons...
Continue Reading →
Regional News

As Viatris seeks growth in eye care, its Ocuphire-partnered dilation drop Ryzumvi wins FDA nod

Viatris just notched a win on its quest to reach $1 billion in eye care sales by 2028. The FDA on Wednesday approved Viatris and Ocuphire’s Ryzumvi, also known as...
Continue Reading →